Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC Meeting Abstract
| Authors: | Yu, H. A.; Oxnard, G. R.; Spira, A. I.; Horn, L.; Weiss, J.; Feng, Y.; West, H. J.; Giaccone, G.; Evans, T. L.; Kelly, R. J.; Fleege, T.; Poondru, S.; Jie, F.; Aoyama, K.; Foley, M. A.; Whitcomb, D.; Keating, A. T.; Krivoshik, A. P. |
| Abstract Title: | Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901795 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.8083 |
| Notes: | Meeting Abstract: 8083 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work